Giant Metastatic Breast Phyllodes Tumour with an Elusive Diagnosis: A Case Report and Literature Review

  • Raquel Basto Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Tatiana Cunha Pereira Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Luís Rei Anatomic Pathology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Fábio Rêgo Salgueiro Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Joana Correia Magalhães Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Maria João Sousa Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Ana Raquel Monteiro Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Filipa Macedo Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Rita Félix Soares
  • Paula Jacinto Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Teresa Carvalho Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal
  • Gabriela Sousa Medical Oncology Department, Portuguese Oncology Institute of Coimbra Francisco Gentil, Coimbra, Portugal

Keywords

Phylloid, tumor, breast, cancer

Abstract

Background: The term phyllodes tumours, which account for less than 1% of breast neoplasms, describes a spectrum of heterogenous tumours with different clinical behaviours. Less than 30% present as metastatic disease. Complete surgical resection is the standard of care so that recurrence rates are reduced. The role of adjuvant chemotherapy or radiation therapy is controversial. Patients with metastatic disease have a median overall survival of around 30 months.

Case description: The authors present the case of a 57-year-old woman with an exuberant left malignant phyllodes tumour with bilateral involvement, as well as lung and axillar metastasis. The patient underwent haemostatic radiation therapy and started palliative chemotherapy with doxorubicin, achieving partial response with significant improvement in quality of life. A posterior simple mastectomy revealed a small residual tumour.

Discussion: Metastatic malignant phyllodes tumours are rare, so therapeutic strategies rely on small retrospective studies and guidelines for soft tissue sarcoma. Palliative chemotherapy protocols include anthracycline-based regimens, either as monotherapy with doxorubicin or doxorubicin together with ifosfamide. With few treatment options, management of these patients must rely on a continuum of care

VIEW THE ENTIRE ARTICLE

References

  • Reinfuss M, Mitu? J, Duda K, Stelmach A, Ry? J, Smolak K. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 1996;77(5):910–916.
  • Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol 2007;14(10):2961–2970.
  • Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, et al. Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. Breast 2009;18(3):165–170.
  • Calhoun K, Allison KH, Kim JN, Rahbar H, Anderson BO. Phyllodes tumors. In: Harris J, Lippman ME, Morrow M, Osborne KC, editors. Diseases of the breast. Philadelphia: Lippincott Williams and Wilkins; 2014, p. 826–837.
  • Jang JH, Choi MY, Lee SK, Kim S, Kim J, Lee J, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol 2012;19(8):2612–2617.
  • Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, et al. Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 2013;88(2):427–436.
  • Kapiris I, Nasiri N, A’Hern R, Healy V, Gui GPH. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol 2001;27(8):723–730.
  • Zeng S, Zhang X, Yang D, Wang X, Ren G. Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: a systematic review and meta-analysis. Mol Clin Oncol 2015;3(3):663–671.
  • Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, et al. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. Breast J 2007;13(6):551–556.
  • Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 2008;70(2):492–500.
  • Papas Y, El Asmar A, Ghandour F, Hajj I. Malignant phyllodes tumors of the breast: a comprehensive literature review. Breast J 2020;26(2):240–244.
  • De Roos WK, Kaye P, Dent DM. Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br J Surg 1999;86(3):396–399.
  • Fajdi? J, Gotovac N, Hrgovi? Z, Kristek J, Horvat V, Kaufmann M. Phyllodes tumors of the breast - diagnostic and therapeutic dilemmas. Onkologie 2007;30(3):113–118.
  • Lu Y, Chen Y, Zhu L, Cartwright P, Song E, Jacobs L, et al. Local recurrence of benign, borderline, and malignant phyllodes tumors of the breast: a systematic review and meta-analysis. Ann Surg Oncol 2019;26(5):1263–1275.
  • Onkendi EO, Jimenez RE, Spears GM, Harmsen WS, Ballman KV, Hieken TJ. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. Ann Surg Oncol 2014;21(10):3304–3309.
  • Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) Program. Cancer 2006;107(9):2127–2133.
  • Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017;18(10):1397–1410.
  • Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Cancer Netw 2007;5(3):324–330.
  • Published: 2021-08-23

    Issue: 2021: Vol 8 No 8 (view)

    Section: Articles

    How to cite:
    1.
    Basto R, Cunha Pereira T, Rei L, Rêgo Salgueiro F, Correia Magalhães J, Sousa MJ, Monteiro AR, Macedo F, Félix Soares R, Jacinto P, Carvalho T, Sousa G. Giant Metastatic Breast Phyllodes Tumour with an Elusive Diagnosis: A Case Report and Literature Review. EJCRIM 2021;8 doi:10.12890/2021_002763.

    Most read articles by the same author(s)